|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.995 USD | +0.38% |
|
-6.76% | -68.77% |
| 06-30 | Plus Therapeutics, Inc. - Special Call | |
| 06-30 | Plus Therapeutics Advances REYOBIQ Clinical Trials and Manufacturing Progress | CI |
Company Valuation: Plus Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 16.13 | 10.65 | 7.915 | 6.781 | 70.4 | 27.39 | - | - |
| Change | - | -33.96% | -25.69% | -14.33% | 938.3% | -61.09% | - | - |
| Enterprise Value (EV) | 16.13 | 10.65 | 7.915 | 6.781 | 70.4 | 27.39 | 27.39 | 27.39 |
| Change | - | -33.96% | -25.69% | -14.33% | 938.3% | -61.09% | 0% | 0% |
| P/E | -0.95x | -0.41x | -0.41x | -0.59x | -44.2x | -1.01x | -1.66x | -13.6x |
| PBR | 1.5x | 1.29x | - | - | - | - | - | - |
| PEG | - | 0x | 0x | 0x | 0.4x | -0x | 0x | 0.2x |
| Capitalization / Revenue | - | 47.6x | 1.61x | 1.16x | 13.5x | 4.35x | 1.43x | 0.6x |
| EV / Revenue | - | 0x | 0x | 0x | 0x | 4.35x | 1.43x | 0.6x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -1.19x | -1.63x | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -1x | -1.45x | -4.92x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -416.2 | -288.7 | -106 | -48.75 | -0.29 | -3.922 | -2.395 | -0.2933 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | 0.224 | 4.913 | 5.824 | 5.213 | 6.295 | 19.14 | 45.31 |
| EBITDA 1 | -11.85 | -19.09 | -12.69 | -13.42 | -13.31 | -23.1 | -16.8 | - |
| EBIT 1 | -12.49 | -19.71 | -13.32 | -14.7 | -15.3 | -27.27 | -18.95 | -5.567 |
| Net income 1 | -13.4 | -20.28 | -13.32 | -12.98 | -22.39 | -26.8 | -18.45 | -5.074 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 393.750 | 118.875 | 43.752 | 28.750 | 12.808 | 3.980 | 3.980 | 3.980 |
| Nbr of stocks (in thousands) | 41 | 89.6 | 181 | 236 | 5,497 | 6,883 | - | - |
| Announcement Date | 2/24/22 | 2/23/23 | 3/5/24 | 3/27/25 | 3/12/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.01x | - | - | - | 27.39M | |
| 34.6x | 6.07x | 18.79x | 0.95% | 49.92B | |
| -23.69x | 348.89x | -22.4x | -.--% | 40.23B | |
| 25.19x | 2.79x | 12.06x | -.--% | 34.55B | |
| 44.97x | 4.49x | 28.67x | -.--% | 33.09B | |
| 30.52x | 8.33x | 21.46x | 0.41% | 27.51B | |
| 32.72x | 5.32x | 24.23x | -.--% | 15.92B | |
| 24.09x | 2.05x | 9x | 1.11% | 13.86B | |
| -22.69x | 14.88x | -22.26x | -.--% | 13.52B | |
| Average | 16.08x | 49.10x | 8.69x | 0.31% | 25.4B | |
| Weighted average by Cap. | 19.77x | 66.17x | 9.63x | 0.32% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PSTV Stock
- Valuation Plus Therapeutics, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
